The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU has been approved in the US for the treatment of adult patients with unresectable or metastatic ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult ...

AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone therapies.

New approval brings the medicine to an earlier treatment setting and a broader patient population.

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

London open The FTSE 100 is expected to open 20 points higher on Tuesday, having closed up 0.02% on Monday at 8,503.71.

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

Geyer Jr., MD, of the UPMC Hillman Cancer Center in Pittsburgh, and co-authors in the New England Journal of Medicine ... trastuzumab deruxtecan (T-DXd, Enhertu) has compiled an impressive ...